Cargando…

An Overview of the Development and Preclinical Evaluation of Antibody–Drug Conjugates for Non-Oncological Applications

Typically, antibody–drug conjugates (ADCs) are made up of a humanized antibody and a small-molecule medication connected by a chemical linker. ADCs’ ability to deliver cytotoxic agents to the specific site with reduced side effects showed promising results in oncology. To date, fourteen ADCs have be...

Descripción completa

Detalles Bibliográficos
Autores principales: Pal, Lal Bahadur, Bule, Prajakta, Khan, Wahid, Chella, Naveen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10385119/
https://www.ncbi.nlm.nih.gov/pubmed/37513995
http://dx.doi.org/10.3390/pharmaceutics15071807
_version_ 1785081324907790336
author Pal, Lal Bahadur
Bule, Prajakta
Khan, Wahid
Chella, Naveen
author_facet Pal, Lal Bahadur
Bule, Prajakta
Khan, Wahid
Chella, Naveen
author_sort Pal, Lal Bahadur
collection PubMed
description Typically, antibody–drug conjugates (ADCs) are made up of a humanized antibody and a small-molecule medication connected by a chemical linker. ADCs’ ability to deliver cytotoxic agents to the specific site with reduced side effects showed promising results in oncology. To date, fourteen ADCs have been approved by the US Food and Drug Administration, and approximately 297 ADCs are in pre-clinical/clinical stages in the oncology area. Inspired by these outcomes, a few scientists explored the potential of antibody–drug conjugates in non-oncological conditions such as arthritis, myasthenia gravis, immunological disorders, and kidney failure. However, there are limited data available on the non-oncological applications of antibody–drug conjugates. This current review focuses on the non-oncological applications of antibody–drug conjugates, their developmental studies, testing procedures, in vitro evaluations, and pre-clinical testing. Additionally, a summary of the restrictions, difficulties, and prospects for ADCs in non-oncological applications is provided.
format Online
Article
Text
id pubmed-10385119
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-103851192023-07-30 An Overview of the Development and Preclinical Evaluation of Antibody–Drug Conjugates for Non-Oncological Applications Pal, Lal Bahadur Bule, Prajakta Khan, Wahid Chella, Naveen Pharmaceutics Review Typically, antibody–drug conjugates (ADCs) are made up of a humanized antibody and a small-molecule medication connected by a chemical linker. ADCs’ ability to deliver cytotoxic agents to the specific site with reduced side effects showed promising results in oncology. To date, fourteen ADCs have been approved by the US Food and Drug Administration, and approximately 297 ADCs are in pre-clinical/clinical stages in the oncology area. Inspired by these outcomes, a few scientists explored the potential of antibody–drug conjugates in non-oncological conditions such as arthritis, myasthenia gravis, immunological disorders, and kidney failure. However, there are limited data available on the non-oncological applications of antibody–drug conjugates. This current review focuses on the non-oncological applications of antibody–drug conjugates, their developmental studies, testing procedures, in vitro evaluations, and pre-clinical testing. Additionally, a summary of the restrictions, difficulties, and prospects for ADCs in non-oncological applications is provided. MDPI 2023-06-24 /pmc/articles/PMC10385119/ /pubmed/37513995 http://dx.doi.org/10.3390/pharmaceutics15071807 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Pal, Lal Bahadur
Bule, Prajakta
Khan, Wahid
Chella, Naveen
An Overview of the Development and Preclinical Evaluation of Antibody–Drug Conjugates for Non-Oncological Applications
title An Overview of the Development and Preclinical Evaluation of Antibody–Drug Conjugates for Non-Oncological Applications
title_full An Overview of the Development and Preclinical Evaluation of Antibody–Drug Conjugates for Non-Oncological Applications
title_fullStr An Overview of the Development and Preclinical Evaluation of Antibody–Drug Conjugates for Non-Oncological Applications
title_full_unstemmed An Overview of the Development and Preclinical Evaluation of Antibody–Drug Conjugates for Non-Oncological Applications
title_short An Overview of the Development and Preclinical Evaluation of Antibody–Drug Conjugates for Non-Oncological Applications
title_sort overview of the development and preclinical evaluation of antibody–drug conjugates for non-oncological applications
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10385119/
https://www.ncbi.nlm.nih.gov/pubmed/37513995
http://dx.doi.org/10.3390/pharmaceutics15071807
work_keys_str_mv AT pallalbahadur anoverviewofthedevelopmentandpreclinicalevaluationofantibodydrugconjugatesfornononcologicalapplications
AT buleprajakta anoverviewofthedevelopmentandpreclinicalevaluationofantibodydrugconjugatesfornononcologicalapplications
AT khanwahid anoverviewofthedevelopmentandpreclinicalevaluationofantibodydrugconjugatesfornononcologicalapplications
AT chellanaveen anoverviewofthedevelopmentandpreclinicalevaluationofantibodydrugconjugatesfornononcologicalapplications
AT pallalbahadur overviewofthedevelopmentandpreclinicalevaluationofantibodydrugconjugatesfornononcologicalapplications
AT buleprajakta overviewofthedevelopmentandpreclinicalevaluationofantibodydrugconjugatesfornononcologicalapplications
AT khanwahid overviewofthedevelopmentandpreclinicalevaluationofantibodydrugconjugatesfornononcologicalapplications
AT chellanaveen overviewofthedevelopmentandpreclinicalevaluationofantibodydrugconjugatesfornononcologicalapplications